- SUPPLEMENTARY MATERIALS -

Table S1. Antibodies used for Western blotting (WB) and immunofluorescence (IFC).

	Antibody	Reference (Company)	WB dilution	IFC dilution
Primary antibodies	**Bcl-xL**	sc-8392 (Santa Cruz Biotechnology®)	1:300	-
	ACC	#3662 (Cell Signalling® Technology)	1:1000	
	Bim	#2933 (Cell Signalling® Technology)	1:1000	-
	Caspase 9	#9508 (Cell Signalling® Technology)	1:500	-
	CD147	sc-71038 (Santa Cruz Biotechnology®)	1:500	1:500
	FAS	sc-48357 (Santa Cruz Biotechnology®)	1:2000	
	GLUT1	ab15309 (AbCam)	1:500	-
	HIF1α	#610958 (BD Biosciences)	1:500	
	HK2	ab104836 (AbCam)	1:2000	
	LDHA	sc-100775 (Santa Cruz Biotechnology®)	1:1000	-
	MCT1	sc-365501 (Santa Cruz Biotechnology®)	1:500	-
		AB3538P (Chemicon®)	-	1:200
	MCT4	sc-50329 (Santa Cruz Biotechnology®)	1:500	1:500
	PARP	#9542 (Cell Signalling® Technology)	1:500	-
	PDK	sc-28783 (Santa Cruz Biotechnology®)	1:500	
Secondary antibodies	**m-IgGκ BP-HRP**	sc-516102 (Santa Cruz Biotechnology®)	1:2500	
	IgG-HRP	sc-2357 (Santa Cruz Biotechnology®)	1:2500	
	Alexa Fluor® 594	A11032 (Invitrogen™)		1:500
	Alexa Fluor® 488	A11008 (Invitrogen™)		1:500
Loading controls	**β-Actin**	sc-8432 (Santa Cruz Biotechnology®)	1:500	
	α-Tubulin	ab15246 (AbCam)	1:2500	



Figure S1. The representative Western blots of baseline levels of cell-death biomarkers in isogenic pairs of urothelial bladder cancer cell lines (A), their respective quantification (B) and the original Western blots (C). Results are representative of similar blots from three independent cell lysates. Intensity ratios relative to α-Tubulin are shown in blue.

A


Relative density of HK2/β-actin
Relative density of PFKL/α-Tubulin
Relative density of PKM2/α-Tubulin
Relative density of CD147/β-actin
Relative density of GLUT1/β-actin
Relative density of PDK/β-actin
Relative density of MCT1/β-actin
Relative density of GLUT3/α-Tubulin
Relative density of MCT4/β-actin
Relative density of LDHA/β-actin
T24
T24R
HT1376
HT1376R
KU1919
KU1919R
*
**

B



Figure S2. Quantification of the Western blot results shown in Figure 2A (A) and the original Western blots (B). Intensity ratios relative to β-Actin and α-Tubulin are shown in red and in blue, respectively. *$p < 0.05$, parental cells *versus* cisplatin-resistant cells.



Figure S3. Glucose consumption of isogenic pairs of urothelial bladder cancer cell lines, assessed in the growth medium 24h post-incubation. ** $p < 0.01$, ***$p < 0.005$, parental cells *versus* cisplatin-resistant cells.

A



B



Figure S4. Quantification of the Western blot results shown in Figure 5 (A) and the original Western blots (B). Intensity ratios relative to α-Tubulin are shown in blue. **$p < 0.01$, parental cells *versus* cisplatin-resistant cells.



Figure S5. Typical ^{1}H NMR spectra of the intracellular extract.